Novartis psoriasis prospect tops J&J's fast-growing Stelara in PhIII

Johnson & Johnson's ($JNJ) Stelara has been cruising lately, most recently posting a 46.8% sales leap in Q3 for the New Jersey pharma giant. But it's got some psoriasis competition waiting in the wings: On Friday, Novartis ($NVS) announced its Phase III prospect, nearing approval after October's unanimous recommendation from an FDA advisory committee, had bested Stelara in a head-to-head trial, reducing psoriasis symptoms by 90%. Report | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.